Global Retirement Partners LLC Purchases 623 Shares of argenex SE $ARGX

Global Retirement Partners LLC grew its position in shares of argenex SE (NASDAQ:ARGX) by 582.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 730 shares of the company’s stock after buying an additional 623 shares during the quarter. Global Retirement Partners LLC’s holdings in argenex were worth $614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Abound Wealth Management lifted its holdings in shares of argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after buying an additional 32 shares during the period. Sound Income Strategies LLC bought a new position in shares of argenex during the 4th quarter valued at $28,000. Ameriflex Group Inc. bought a new position in shares of argenex during the 3rd quarter valued at $32,000. Aventura Private Wealth LLC bought a new position in shares of argenex during the 4th quarter valued at $38,000. Finally, Sunbelt Securities Inc. bought a new position in shares of argenex during the 3rd quarter valued at $36,000. 60.32% of the stock is owned by institutional investors.

Analyst Ratings Changes

ARGX has been the topic of several research analyst reports. Oppenheimer lowered their price target on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. Robert W. Baird raised their target price on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Guggenheim raised their target price on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Wells Fargo & Company raised their target price on argenex from $1,247.00 to $1,260.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, argenex currently has a consensus rating of “Moderate Buy” and an average price target of $1,017.78.

argenex Stock Performance

Shares of NASDAQ ARGX opened at $820.63 on Thursday. The company has a market cap of $51.03 billion, a P/E ratio of 36.54, a P/E/G ratio of 1.28 and a beta of 0.46. The firm’s fifty day moving average is $773.63 and its two-hundred day moving average is $815.24. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The firm had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. As a group, analysts forecast that argenex SE will post 25.27 EPS for the current fiscal year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.